---
figid: PMC6287026__fphar-09-01426-g001
figtitle: Possible mechanisms of synergistic actions of the LABA/LAMA combination
  against inflammation
organisms:
- Mus musculus
- Rattus norvegicus
- Cavia porcellus
- Homo sapiens
- Bos taurus
- Escherichia coli
organisms_ner:
- Mus musculus
- Homo sapiens
- Rattus norvegicus
- Drosophila melanogaster
pmcid: PMC6287026
filename: fphar-09-01426-g001.jpg
figlink: /pmc/articles/PMC6287026/figure/F1/
number: F1
caption: Possible mechanisms of synergistic actions of the LABA/LAMA combination against
  inflammation. (A) Synergistic inhibitory effect of LABA/LAMA against ACh release
  from airway epithelial cells. Signaling via β2AR inhibits the function of OCT1,
  a transporter for the release of acetylcholine from airway epithelial cells, whereas
  signaling via M3 possibly upregulates the function of OCT1. Therefore, the LABA/LAMA
  combination synergistically inhibits the release of ACh. (B) Synergistic inhibitory
  effect of LABA/LAMA against the production of inflammatory mediators. Signaling
  via β2AR activates AC-cAMP-PKA signaling pathway. PKA inhibits ERK and p38MAPK pathways.
  In contrast, signaling via M3 activates PKC, which results in the activation of
  NF-κB. The combination of LABA and LAMA therefore possibly inhibits the production
  of pro-inflammatory mediators synergistically via inhibiting both MAPK and NF-κB
  pathways. ACh, acetylcholine; AC, adenylate cyclase; β2AR, beta-2 adrenergic receptor;
  cAMP, cyclic adenosine monophosphate; CHT1, high-affinity choline transporter 1;
  ERK, extracellular signal-regulated kinase; LABA, long-acting β2 agonist; LAMA,
  long-acting muscarinic antagonist; MAPK, mitogen-activated protein kinase; M3, acetylcholine
  muscarinic M3 receptor; NF-κB, nuclear factor-kappa B; OCT1, organic cationic transporter
  1; PKA, protein kinase A; PKC, protein kinase C.
papertitle: 'The Cholinergic Pathways in Inflammation: A Potential Pharmacotherapeutic
  Target for COPD.'
reftext: Mitsuhiro Yamada, et al. Front Pharmacol. 2018;9:1426.
year: '2018'
doi: .na.character
journal_title: .na.character
journal_nlm_ta: .na.character
publisher_name: .na.character
keywords: .na.character
automl_pathway: 0.9363368
figid_alias: PMC6287026__F1
figtype: Figure
redirect_from: /figures/PMC6287026__F1
ndex: 20bdd17b-df06-11ea-99da-0ac135e8bacf
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC6287026__fphar-09-01426-g001.html
  '@type': Dataset
  description: Possible mechanisms of synergistic actions of the LABA/LAMA combination
    against inflammation. (A) Synergistic inhibitory effect of LABA/LAMA against ACh
    release from airway epithelial cells. Signaling via β2AR inhibits the function
    of OCT1, a transporter for the release of acetylcholine from airway epithelial
    cells, whereas signaling via M3 possibly upregulates the function of OCT1. Therefore,
    the LABA/LAMA combination synergistically inhibits the release of ACh. (B) Synergistic
    inhibitory effect of LABA/LAMA against the production of inflammatory mediators.
    Signaling via β2AR activates AC-cAMP-PKA signaling pathway. PKA inhibits ERK and
    p38MAPK pathways. In contrast, signaling via M3 activates PKC, which results in
    the activation of NF-κB. The combination of LABA and LAMA therefore possibly inhibits
    the production of pro-inflammatory mediators synergistically via inhibiting both
    MAPK and NF-κB pathways. ACh, acetylcholine; AC, adenylate cyclase; β2AR, beta-2
    adrenergic receptor; cAMP, cyclic adenosine monophosphate; CHT1, high-affinity
    choline transporter 1; ERK, extracellular signal-regulated kinase; LABA, long-acting
    β2 agonist; LAMA, long-acting muscarinic antagonist; MAPK, mitogen-activated protein
    kinase; M3, acetylcholine muscarinic M3 receptor; NF-κB, nuclear factor-kappa
    B; OCT1, organic cationic transporter 1; PKA, protein kinase A; PKC, protein kinase
    C.
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - Lama1
  - Adrb1
  - Bfar
  - ac
  - Nfkb1
  - Ephb2
  - Mapk1
  - Slc5a7
  - Pou2f1
  - Slc22a1
  - Mapk14
  - LAMA1
  - FGFR3
  - ADRB2
  - NR1H4
  - BFAR
  - PRRT2
  - PRKCA
  - PRKCB
  - PRKCD
  - PRKCE
  - PRKCG
  - PRKCH
  - PRKCI
  - PRKCQ
  - PRKCZ
  - PRKD3
  - ADCY1
  - ADCY2
  - ADCY3
  - ADCY4
  - ADCY5
  - ADCY6
  - ADCY7
  - ADCY8
  - ADCY9
  - ADCY10
  - NFKB1
  - PRKAR1A
  - PRKAR1B
  - PRKAR2A
  - PRKAR2B
  - PRKACA
  - PRKACB
  - PRKACG
  - EPHB2
  - MAPK1
  - MAPK3
  - SLC5A7
  - POU2F1
  - SLC22A1
  - Prkcg
  - Ephb1
  - Slc6a8
  - lama
  - LanA
  - achi
  - emc
  - B-H2
  - B-H1
  - hh
  - .na.character
  - inaC
  - Pkc98E
  - aPKC
  - Pkc53E
  - Dif
  - dl
  - Rel
  - Pka-C1
  - Pka-R2
  - Pka-C3
  - Pka-R1
  - Pka-C2
  - CkIIbeta
  - Andorra
  - Anp
  - Acam
  - Erk7
  - rl
  - Cht10
  - nub
  - p38b
  - p38a
  - p38c
  - Acetyl-CoA
  - Choline
---
